BEAM ▼ -0.5% - Beam Therapeutics Inc.
$BEAM - Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress
27-OCT-2026 07:00 AM ET
Share this post
More filings for $BEAM
BEAM ▲ +1.3% - Beam Therapeutics Inc.Oct 13, 2026BEAM ▲ +2.7% - Beam Therapeutics Inc.Sep 10, 2026BEAM ▲ +3.7% - Beam Therapeutics Inc.Sep 8, 2026BEAM ▲ +3.5% - Beam Therapeutics Inc.Sep 8, 2026BEAM ▼ -0.8% - Beam Therapeutics Inc.Sep 1, 2026BEAM - Beam Therapeutics Inc. - SEC Filing Update (13-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 13, 2026
View full $BEAM filing history →💬 Comments
Loading comments…
Leave a comment